Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02196857

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to learn if 5-azacitidine and sorafenib can help to control the disease in patients with AML and high risk MDS with FLT3-ITD mutation. The safety of this drug combination will also be studied.

Status: 
Recruiting
Study Date: 
Sun, 02/01/2015 to Fri, 02/02/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Azacytidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle. Other Names: 5-Azacytidine 5-AZA Vidaza 5-AZC AZA-CR Ladakamycin NSC-102816 Drug: Sorafenib 400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle. Other Names: Nexavar BAY 43-9006